Effect of Tocilizumab on “Ventilator Free Days” Composite Outcome in SARS-CoV-2 Patients: A Retrospective Competing Risk Analysis
, , , , , , , , et
14 janv. 2023
À propos de cet article
Catégorie d'article: Original paper
Publié en ligne: 14 janv. 2023
Pages: 1 - 7
DOI: https://doi.org/10.2478/rjaic-2022-0001
Mots clés
© 2022 Ahmed F. Mady et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Results of competing risk analysis, and Cox proportional regression:
| Competing Risk Regression | SHR: 2.7 (1.2 – 6.3) | 0.02 |
| Cox Proportional Hazard | HR: 0.49 (0.25 – 0.97) | 0.04 |
Results of secondary outcomes:
| ICU mortality (n, %) | 11 (37.9%) | 18 (62%) | −3.9 to 48.5 | 0.1 |
| Actual VFD: median (IQR) | 10 (0 – 13) | 0 (0 – 2.25) | 1.1 – 8.3 | 0.02 |
| Positive cultures (n, %) | 16 (55.2%) | 10 (34.5%) | −7.11 to 45.4 | 0.1 |
Demographic and clinical characteristics of study groups before and after matching:
| Age: Median (IQR) | 59 (52.5 – 60.25) | 51 (44 – 57) | 0.0001 | 59 (52.5 – 60.25) | 57 (51.75 – 63.25) | 0.9 |
| Gender: Male (n, %) | 21 (72.4%) | 262 (67.9%) | 0.6 | 21 (72.4%) | 20 (69%) | 0.8 |
| SOFA score Median (IQR) | 4 (4 – 5) | 3 (4 – 5) | 0.0001 | 4 (4 – 5) | 4 (4 – 4.25) | 0.2 |
| BMI Median (IQR) | 27 (23.3 – 31.2) | 25.8 (22.6 – 29.4) | 0.2 | 27 (23.3 – 31.2) | 25.3 (21.85 – 28.63) | 0.1 |
| Smoking (n, %) | 10 (34.5%) | 131 (33.9%) | 0.9 | 10 (34.5%) | 9 (31%) | 0.8 |
| Anti-viral (n, %) | 11 (37.9%) | 154 (39.9%) | 0.8 | 11 (37.9%) | 12 (41.4%) | 0.8 |
| Steroids (n, %) | 17 (58.6%) | 245 (63.5%) | 0.6 | 17 (58.6%) | 16 (55.2%) | 0.8 |